News >

Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months

Jason Harris
Published: Monday, Apr 02, 2018

Dr. Philippe Armand

Philippe Armand, MD, PhD
In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate (ORR) of 69% in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT).1

ORR was 69% (95% CI, 63%-75%)as assessed by an independent review committee (IRC). Sixteen percent of patients had complete response (CR) and 53% had partial response (PR). Per investigator assessment, ORR was 72%, with 33% of patients achieving CR.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication